Literature DB >> 2061835

Pharmacology of nicotinic receptor-mediated inhibition in rat dorsolateral septal neurones.

L A Wong1, J P Gallagher.   

Abstract

1. Intracellular electrophysiological techniques were employed to investigate the effects of nicotinic receptor stimulation on rat dorsolateral septal nucleus (DLSN) neurones in a submerged rat brain slice preparation. 2. Acetylcholine (in the presence of the muscarinic antagonist, atropine), nicotine or dimethylphenylpiperazinium (DMPP), applied either by pressure ejection or superfusion, produced predominantly a membrane potential hyperpolarization. 3. Following concentration-response comparisons, DMPP appeared to exhibit fewer desensitizing properties and greater efficacy than nicotine with half-maximal hyperpolarizing responses attainable at 3 and 10 microM, respectively. 4. Pharmacological analyses revealed that the agonist-induced membrane hyperpolarization was sensitive to antagonism by mecamylamine (50-100 microM) and neuronal bungarotoxin (0.2-0.3 microM), but not alpha-bungarotoxin (0.5-1.0 microM), curare (10-50 microM) or dihydro-beta-erythroidine (50-100 microM). 5. Hyperpolarizing responses to DMPP were found to reverse near the equilibrium potential for potassium and were sensitive to changes in extracellular potassium concentration as predicted by the Nernst equation. Under single-electrode voltage clamp, application of DMPP produced an outward current (75-100 pA) which approached reversal at around -88 mV. These findings indicated that the hyperpolarizing response to nicotinic receptor stimulation was mediated by changes in membrane permeability to potassium. 6. DMPP-induced membrane hyperpolarization resulted from a direct action on postsynaptic DLSN neurones since the response persisted under conditions of superfusion with calcium-free/high-magnesium media or tetrodotoxin; both conditions blocked orthodromically induced neurotransmission. The hyperpolarizing response remained unaltered in TTX but was diminished in calcium-free/high-magnesium media. Further studies revealed blockade of the DMPP response following intracellular injection of EGTA. This response was also sensitive to antagonism by various calcium-dependent potassium channel blockers including apamin, barium and tetraethylammonium. 7. Our studies reveal a novel class of CNS nicotinic receptor whose action upon stimulation by an agonist results in a membrane hyperpolarization via a calcium-dependent increase in potassium ion conductance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2061835      PMCID: PMC1181508          DOI: 10.1113/jphysiol.1991.sp018553

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  51 in total

1.  Cholinergic mechanisms in the cerebellar cortex.

Authors:  I McCance; J W Phillis
Journal:  Int J Neuropharmacol       Date:  1968-09

Review 2.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

3.  Chemoreceptors for serotonin (5-HT), acetylcholine (ACh), bradykinin (BK), histamine (H) and gamma-aminobutyric acid (GABA) on rabbit visceral afferent neurons.

Authors:  H Higashi; N Ueda; S Nishi; J P Gallagher; P Shinnick-Gallagher
Journal:  Brain Res Bull       Date:  1982-01       Impact factor: 4.077

4.  Acetylcholine hyperpolarizes central neurones by acting on an M2 muscarinic receptor.

Authors:  T M Egan; R A North
Journal:  Nature       Date:  1986 Jan 30-Feb 5       Impact factor: 49.962

5.  Two types of muscarinic response to acetylcholine in mammalian cortical neurons.

Authors:  D A McCormick; D A Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

6.  A comparative study of some convulsant substances as gamma-aminobutyric acid antagonists in the feline cerebral cortex.

Authors:  R G Hill; M A Simmonds; D W Straughan
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

7.  Actions of serotonin recorded intracellularly in rat dorsal lateral septal neurons.

Authors:  M Joëls; J P Gallagher
Journal:  Synapse       Date:  1988       Impact factor: 2.562

8.  Selective antagonism of nicotine actions in the rat cerebellum with alpha-bungarotoxin.

Authors:  R de la Garza; T J McGuire; R Freedman; B J Hoffer
Journal:  Neuroscience       Date:  1987-12       Impact factor: 3.590

9.  Pharmacological properties of cholinoceptive neurones in the medulla and pons of the cat.

Authors:  P B Bradley; B N Dhawan; J H Wolstencroft
Journal:  J Physiol       Date:  1966-04       Impact factor: 5.182

10.  Mechanisms of action of acetylcholine in the guinea-pig cerebral cortex in vitro.

Authors:  D A McCormick; D A Prince
Journal:  J Physiol       Date:  1986-06       Impact factor: 5.182

View more
  5 in total

1.  Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal alpha 7 nicotinic receptor.

Authors:  D Bertrand; J L Galzi; A Devillers-Thiéry; S Bertrand; J P Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

2.  Distinct patterns of exocytosis elicited by Ca2+, Sr2+ and Ba2+ in bovine chromaffin cells.

Authors:  Andrés M Baraibar; Ricardo de Pascual; Marcial Camacho; Natalia Domínguez; J David Machado; Luis Gandía; Ricardo Borges
Journal:  Pflugers Arch       Date:  2018-06-21       Impact factor: 3.657

3.  Role of Ca2+ ions in nicotinic facilitation of GABA release in mouse thalamus.

Authors:  C Léna; J P Changeux
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

Review 4.  Thymopoietin, a thymic polypeptide, potently interacts at muscle and neuronal nicotinic alpha-bungarotoxin receptors.

Authors:  M Quik
Journal:  Mol Neurobiol       Date:  1992       Impact factor: 5.590

5.  Activation of nicotinic acetylcholine receptors augments calcium channel-mediated exocytosis in rat pheochromocytoma (PC12) cells.

Authors:  A B Harkins; A P Fox
Journal:  J Gen Physiol       Date:  1998-02       Impact factor: 4.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.